Molecular threat of splicing factor mutations to myeloid malignancies and potential therapeutic modulations

HIGHLIGHTS

• who: Fangliang Zhang and Liang Chen from the Hubei Key Laboratory of Cell Homeostasis, RNA Institute, College of Life Sciences, Wuhan University, Wuhan, China have published the research: Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations, in the Journal: Biomedicines 2022, 10, 1972. of /2022/

SUMMARY

Splicing factors are frequently mutated in a variety of hematologic malignancies, including myelodysplastic syndromes (MDS) that may progress to acute myeloid leukemia (AML). Among all splicing factor mutations, major heterozygous point mutations in Splicing factor 3B subunit 1 (SF3B1), U2 small_nuclear_RNA auxiliary . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.